# Neurological complications in recipients after living donor liver transplantation

#### **Thesis**

Submitted for partial fulfillment of the MD degree in Neurology

#### By:

#### **Mohamed Ibrahim Mohamed Hassan Khalil**

M.B.B.Ch., M.Sc. Neuropsychiatry

### Supervised by

### Prof. Dr. Eman Ahmed Elbanhawy

Professor of Neurology Faculty of Medicine, Cairo University

### Prof. Dr. Ashraf Elsherbiny Abdelhady

Professor of internal medicine National research centre

#### Prof. Dr. Hanan AbdAllah Amer

Professor of Neurology Faculty of Medicine, Cairo University

### **Dr. Sandra Ahmed**

Lecturer of Neurology
Faculty of Medicine, Cairo University

Faculty of Medicine Cairo University 2015





### **ACKNOWLEDGMENT**

### "First and Foremost, Thanks are Due to ALLAH, The Beneficent and Merciful of All"

I would like to express my cardinal thanks and deepest gratitude to *Professor Eman El-Banhawy*, *Professor of neurology*, *Cairo University*, not only for giving me this chance to work under her supervision, but also for the great scientific help, valuable guidance, professional assistance and kind supervision.

I would also like to express my deep thanks and gratitude to *Professor Ashraf elsherbiny*, *Professor of internal medicine*, *National Research Centre*, for his kind supervision and his great help in practical part of this work.

Whatever I say or write, I will never be able to express my deep feelings and profound gratitude to *Professor Hanan Amer, Professor of neurology, Cairo University*, for suggesting and planning the design of the entire work, kind supervision, great scientific help and for being kind enough to follow closely every step in the whole work. Without her valuable guidance, the performance of this work would have been much more difficult.

I wish to express my deep appreciation and profound gratitude to *Dr. Sandra Ahmed, Lecturer of neurology, Cairo University* for her kind guidance, assistance and encouragement during the progress of this work.

Special thanks and gratitude to *Professor Hala Zaki*, *Professor and Head of Internal Medicine department*, *National Research Centre*, for her kind guidance, assistance, continuous scientific help and her unlimited encouragement and support.

Finally, no words can express my gratitude and deepest appreciation to my family and my colleagues for their neverending care and support.

### **Contents**

List of Abbreviations	i
List of Tables	iv
List of Figures	vi
Abstract	viii
Introduction	ix
Aim of the Work	хi
Review of Literature	
Chapter I	
Liver and nervous system	1
Chapter II	
Neurological complications of organ transplantation	٤٩
Chapter III	
Liver transplantation	98
Chapter IV	
Neurological complications of liver Transplantation	١١٨
Subjects and Methods	168
Results	176
Discussion	201
Summary & Conclusion	218
Recommendations	225
References	227
Appendix	271
Arabic Summary	

### **List of Abbreviations**

AEDs : Antiepileptic Drugs AFB : Acid Fast Bacilli

AIDP : Acute Inflammatory Demyelinating Polyneuropathy

BBB : Blood Brain Barrier

Cho : Choline

CIDP : Chronic Inflammatory Demyelinating Polyneuropathy

CIM : Critical Illness Myopathy

CIP : Critical Illness Polyneuropathy

Cis : Calcineurin Inhibitors
CK : Creatinine Kinase
CMV : Cytomegalovirus

CNS : Central Nervous System

COA : Co Enzyme A

CPM : Central Pontine Myelinolysis

Cr : Creatine CS : Cyclosporine

CSF : Cerebrospinal Fluid

CT : Computerized Tomography

CVST : Cerebral Venous Sinus Thrombosis

Cx : Culture and sensitivity

DDLT : Deceased Donor Liver Transplantation

DM : Diabetes Mellitus
EBV : Epstein-Barr Virus
EEG : Electroencephalography
EMG : Electromyography

EPS : Extrapyramidal symptoms

ESLD : End Stage Liver Disease

FLAIR : Fluid Attenuated Inversion Recovery

FTA-ABS : Fluorescent Treponemal Antibody Absorbed Test

GABA : Gamma Amino Butyric Acid GBS : Guillian Barre Syndrome GVHD : Graft Versus Host Disease HBS : Hepatobiliary Scintigraphy

### **List of Abbreviations**

HBV : Hepatitis B virus

HCC : Hepatocellular Carcinoma

HCV : Hepatitis C virus

HE : Hepatic Encephalopathy

HEV : Hepatitis E virus

HHV-6 : Human herpes virus-6

HIE : Hypoxic Ischemic Encephalopathy
HIV : Human Immune deficiency virus

HSCT : Hematopoietic stem cell transplantation

HSV : Herpes Simplex Virus

ICH : Intracerebral Hemorrhage

ICU : Intensive Care Unit

INH : Isoniazide

IRS : Immune Reconstitution Syndrome

IV : Intravenous

JC Virus : John Cunningham Virus

LDLT : Living Donor liver transplantation

LOC : Level of Conciousness

LP : Lumbar puncture

LT : Liver Transplantation

MHA-TP : Microhemagglutination Treponemal Test

MMF : Mycophenolate Mofetil

MRI : Magnetic Resonance ImagingMRV : Magnetic Resonance Venography

NAA : N-acetyl Aspartate

NC : Neurological ComplicationsNCS : Nerve Conduction Study

OHE : Overt Hepatic Encephalopathy
OLT : Orthotopic Liver transplantation

### **List of Abbreviations**

PBC : Primary Biliary CirrhosisPCR : Polymerase Chain ReactionPET : Positron emission tomography

PML : Progressive Multifocal Leucoencephalopathy

PSC : Primary Sclerosing Cholangitis

PTLD : Posttransplant Lymphoproliferative Disorder RPLE : Reversible Posterior Leucoencephalopathy

SHE : Subminimal Hepatic Encephalopathy

SIP : Sickness Impact Profile

SPSS : Statistical Package for Social Sciences

SSEP : Somatosensory Evoked Potential

SSRI : Selective Serotonin Reuptake Inhibitors

TBI : Traumatic Brain Injury

TMP/SMX : Trimethoprim/SulfamethoxazoleTSH : Thyroid Stimulating Hormone

VDRL : Venereal Disease Research Laboratory

VZV : Varicella Zoster Virus WML : White Matter Lesions

WNV : West Nile Virus

## List of tables

Table	Title	Page
1	The incidence of neurologic complications after different organs transplantation	52
2	The risk factors for cerebrovascular events in posttransplant patients	132
3	Diagnostic criteria for CNI neurotoxicity	136
4	Differential diagnosis of drug toxicities and their management	139
5	Comparison of white matter diseases affecting transplant patients	145
6	Opportunistic infections affecting transplant patients	154
7	Risk factor/mechanisms of neuropsychiatric disorders	160
8	Demographic features of the studied patients	177
9	Indications of liver diseases of the studied patients.	178
10	Neurological complications in studied patients	181
11	Descriptive statistics of different laboratory variables of the studied patients	183
12	C.T or MRI findings in patients with neurological complications	185

# **List of tables (Cont.)**

Table	Title	Page
13	FK patients' number and percentage of drug side effects	187
14	Number and percentage of patients in the subgroups	188
15	Comparison between mean values of different laboratory investigations in patient subgroups classified according to neurological complications.	190
16	Association between indications of liver disease and neurological complications in the two studied patients' subgroups	193
17	Association between CT-MRI and neurological complications in patients' subgroups.	194
18	Association between FK drug side effects and neurological complications in the two studied patients' subgroups.	195
19	Association between cyclosporine drug side effects in the two studied patients' subgroups.	196
20	Correlation between final complications and age, DM and HTN in all patients	196
21	Correlation between drugs used and different laboratory parameters in patients.	198
22	Correlation between drugs used and different laboratory parameters in neurologically complicated patients	200

# **List of Figures**

Fig.	Title	Page
1	Neurotoxicity of calcineurin inhibitors manifests on MRI with predominantly posterior hyperintensities on T2-weighted and FLAIR imaging sequences	71
2	Causes of postoperative encephalopathy in LT	124
3	Algorithm for management of postoperative encephalopathy	125
4	Algorithm for evaluation and management of a patient with seizures following liver transplantation	130
5	MRI Flair sequence showing a hyperintense central pontine lesion in a LT patient	144
6	MRI FLAIR sequence showing increased signal in the hemispheric white matter (Right side) with improvement 11 days after discontinuation of tacrolimus (Left side)	146
7	The male and female percent in our patients	177

# **List of Figures(cont.)**

8	Indications of liver diseases of the studied patients	179
9	The percent of positive radiological findings (C.T. or MRI) among neurologically complicated patients	184
10	Final neurological complications in the studied patients	189
11	Comparison between mean values of hemoglobin in the two studied groups	191
12	Correlation between FK506 and total bilirubin in all patients	199

### **Abstract**

**Background and Objective**: Neurological complications (NC) affects up to one third of patients after Liver transplantation (LT). The aim of this study is to assess the incidence, risk factors and clinical presentation of NC after liver transplantation in patients who underwent living donor liver transplantation (LDLT) in Egypt.

**Methods:** Between November 2011 and December 2013, 149 patients from diffrent centers were observed for one month after LDLT and evaluated by full general and neurological examination, assessment of encephalopathy by West Haven classification, full laboratory investigations including drug levels, and brain CT and/or MRI.

**Results**: 46 patients (30.9%) developed neurological complications 30 of which (20.1%) developed side effects related to Tacrolimus (FK-506) and 2 patients (1.3%) developed side effects related to cyclosporine. The most common neurological complications were Encephalopathy (14.1%) while the least were both Central pontine myelinolysis and Meningoencephalitis (0.7%). Patients were classified into complicated and noncomplicated groups. The mean Serum level of Tacrolimus (FK-506) was higher in complicated than noncomplicated patients yet both were within the normal therapeutic range with no statistically significant difference. A highly significant association was found regarding the relation between FK-506 and neurological complications in both groups. Neither the age nor the preoperative risk factors (diabetes mellitus, hypertension) had significant correlation with the early postoperative neurological complications. In all patients, there was no statistical significant correlation between FK506 and the other studied parameters while there was a positive correlation between FK506 and total bilirubin (r= 0.226; p= 0.006). FK506 was positively correlated with both direct bilirubin (r= 0.160; p= 0.053) and ammonia (r= 0.146; p= 0.078) statistical significant correlation were found between cyclosporine and different studied parameters. In neurologically complicated patients, FK506 was positively correlated with both total bilirubin (r= 0.272; p= 0.089) and direct bilirubin (r= 0.281; p= 0.079) vet still insignificant (borderline insignificant). Finally, no correlation was observed between the primary cause of liver disease and the NCs reported.

**Conclusion:** There was a high incidence of neurological complications after LT, the most common complications following LT were encephalopathy, delirium, hallucinations, delusions and seizures. NC can occure even with normal serum levels of FK506.

**Key words**: Liver Transplantation, Neurological complication, Encephalopathy, Immunosuppression

### Introduction

Liver transplantation has become a lifesaving therapy for many types of end stage liver disease, however during the past decade; a critical shortage of cadaveric organs for adults in need of liver transplants has developed. During this time, the waiting period for liver transplantation and the rate of death among patients on waiting lists have been increased. Therefore, living donor liver transplantation (LDLT) has become an important tool to treat end stage liver disease due to the lack of such cadaveric donors (Lee et al., 2008). Over the past several advances surgical techniques, organ preservation, decades. in immunosuppressive therapy, and early detection of postoperative complications have increased survival rates after liver transplantation (Caiado et al., 2007).

Liver transplantation (LT) is the only curative treatment in patients with end-stage liver disease. The first LT was performed in 1963 (Starzl et al., 1963). Initially, the most common reason for death post-LT was an acute or chronic rejection of the graft. Then, the introduction of immunosuppressive treatment increased the survival rate from 20% to nearly 80% (Starzl et al., 1985), but postoperative complications remain a significant source of morbidity and mortality (Mazariegos et al., 1999). Of all the complications post-LT, the neurological complications (NC) are particularly relevant, since they affect up to a third of transplanted patients (Wang et al., 2000).

With the rapid development of transplant technique and immunosuppressive therapy, orthotopic liver transplantation (OLT) has been carried out all over the world and accepted as one of the most effective treatments for the patients with end-stage liver diseases. However, postoperative complications are still the most important causes resulting in death of patients undergoing OLT (*Dhar et al.*, 2008).

The incidences of posttransplant cerebrovascular complications or intracranial hemorrhage were 2.2%–3.9% in United States (Saner et al., 2006), 3.3% in United Kingdom (Lewis et al., 2003), 3.7% in Chile (Uribe et al., 2003), 6% in Spain (Pujol et al., 1994), 6.5% in Hong Kong (Wang et al., 2000).